key: cord-0882306-z4lutyjr
authors: Seitlinger, Joseph; Wollbrett, Christophe; Mazzella, Antonio; Schmid, Severin; Guerrera, Francesco; Nkomo, Douglas Banga; Hassan, Mohamed; Brindel, Aurélien; Ruuth-Praz, Julia; Schmitt, Pierre; Clément-Duchêne, Christelle; Douiri, Nawal; Reeb, Jérémie; Prisciandaro, Elena; Siat, Joelle; Spaggiari, Lorenzo; Ruffini, Enrico; Filosso, Pierluigi; Ferri, Lorenzo; Santelmo, Nicola; Spicer, Jonathan; Renaud, Stéphane
title: Safety and feasibility of thoracic malignancy surgery during the COVID-19 pandemic.
date: 2020-12-14
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2020.12.001
sha: 044b9ea99e41361b41dfe47d1cd596719b93e89c
doc_id: 882306
cord_uid: z4lutyjr

Background The COVID-19 pandemic has decreased surgical activity, particularly in the field of oncology, due to the suspicion of a higher risk of COVID-19-related severe events. We aimed to investigate the feasibility and safety of thoracic cancer surgery in the most impacted European and Canadian regions during the COVID-19 pandemic. Methods We prospectively collected data on thoracic malignancies surgeries from January 1 to April 30, 2020. We included patients from six high-volume thoracic surgery departments: Nancy and Strasbourg (France), Freiburg (Germany), Milano and Torino (Italy), and Montreal (Canada). The centers involved in this research are all located in the most impacted regions of the countries concerned. An assessment of COVID-19-related symptoms, polymerase chain reaction (PCR)-confirmed COVID-19 infection, rates of hospital and intensive care unit admissions and deaths was performed for each patient. Every death was tested for COVID-19 by PCR. Results In the study period, 731 patients who underwent 734 surgical procedures were included. In the whole cohort, 9 cases (1.2%) of COVID-19 were confirmed by PCR, including 5 in-hospital contaminants. Four patients (0.5%) needed readmission for oxygen requirements. In this subgroup, two patients (0.3%) needed ICU and mechanical ventilatory support. The total number of deaths in the whole cohort was 22 (3%). A single death was related to COVID-19 (0.14%). Conclusions Maintaining surgical oncologic activity in the era of the COVID-19 pandemic seems safe and feasible, with very low postoperative morbi-mortality. To continue to offer the best care to non-COVID-19 patients, reports on other diseases are urgently needed.

COVID-19 has become the largest pandemic that the world has faced in the last century 1 

Europe has rapidly been defined as the epicenter of the pandemic by the World Health Organization (WHO). The first epidemic outbreak in Europe was located in northern Italy, particularly in Lombardy 2 . During the progression of the epidemic in Europe, the spread started in North America. In Canada, Quebec was considered the epicenter of the infection. Consequently, healthcare systems worldwide had to adapt to this dramatic increase in COVID-19-infected patients to offer them best care. Hence, based on the recommendations of scientific societies, a large proportion of elective surgeries were postponed. This decision was reinforced by publications from China on cancers.

Indeed, reports from China showed an increased risk of death and/or ICU admission in cases of cancer 3, 4 . Hence, the precautionary principle led to a dramatic decrease in malignancy management worldwide, including thoracic cancers 5, 6 .

However, it seems now that the world will still have to address COVID-19 for an indefinite period of time and taking care of other health disorders is still relevant. Large-scale data on cancer surgeries are thus more than necessary. Here, we report the first and largest international multi-institutional cohort of thoracic malignancy surgeries in six high-volume thoracic surgery departments that have been the most severely impacted by COVID-19.

This study was approved by the Ethics Committee of the French Society of Thoracic and Cardiovascular Surgeons (Approval Number: CERC-SFCTCV-2020-07-03-14-REST).

A retrospective review of prospective databases was reviewed from January 1 to April 30, 2020, from Nancy and Strasbourg (France), Freiburg (Germany), Milano and Torino (Italy), and Montreal (Canada). All of these thoracic surgery centers are located in the regions that have been most impacted by the pandemic in their respective countries. These countries officially reported their first case of COVID-19 at the end of February, a few days apart, starting with Italy (February 21, 2020). Because cancer patients are considered to be at higher risk in the 6 weeks following surgery, we decided to review patients starting on January 1, given that the virus likely began to spread in these regions before the first cases were declared. Nevertheless, in France, the first case of COVID-19 was J o u r n a l P r e -p r o o f retrospectively diagnosed on December 20, 2019, by polymerase chain reaction (PCR). One can thereby speculate that on January 1, 2020, the virus was already present, at least in Europe. We then divided patients into 2 groups based on whether they were operated on before (group 1) or after (group 2) lockdown in each country (i.e., March 9 in Italy, March 17 in France, March 22 in Quebec). In Germany, there has been no lockdown similar to that in France, Italy and Canada. We have therefore chosen March 22 as the equivalent of lockdown for Germany.

After lockdown, specific measures were taken with the goal of avoiding operations on COVID-19+ patients. In France, the day before surgery, patients were assessed by phone call for the existence or absence of symptoms related to COVID-19 or contact in the previous 14 days with individuals confirmed to have COVID-19 or harboring COVID-19-related symptoms. More recently, a chest CT scan without contrast was systematically performed the day before surgery to rule out COVID-19related infiltrate. In cases of high suspicion, patients were tested by PCR. In Italy and Canada, healthcare institutions routinely performed PCR for COVID-19 prior to each hospitalization in surgical departments. In Germany, the PCR research for COVID-19 was only performed in patients with contact or symptoms. Nevertheless, PCR-positive patients were rescheduled and retested 2 weeks later regardless of the inclusion center.

Since the European Institute of Oncology (EIO) in Milano was decided to be a COVID-free area, patients with a diagnosis of COVID-19 were referred to other centers.

Since May, in France, as in Italy and Canada, all patients undergoing surgery have had PCR test before surgery. In Germany, COVID-19 PCR test is only performed in symptomatic patients prior to surgery.

To date, all patients and/or family doctors have been contacted by phone calls to assess the appearance of COVID-19-related symptoms or to determine PCR-confirmed COVID-19 or death.

The primary endpoints were PCR-confirmed COVID-19 disease, rates of hospital/ICU admission (defined as severe cases) and death.

Detailed characteristics of the population are disclosed in Table 1 . Meanwhile wedge resections were usually performed for metastasectomy (147/152, 96.7%), five were performed for localized NSCLC due to poor pulmonary function Table 2 summarizes the case exposure of COVID-19 patients (in hospital, in ICU, cessation of activity in the operating room) in the different hospitals in our study.

A total of 122 COVID-19 PCR tests were performed during lockdown, most of them (107, 87.7%) were done routinely before hospitalization, and 15 (12.3%) were done in symptomatic patients. Only 23 patients were screened by CT scan before hospitalization. One patient required a 15-day delay due to a positive test prior to admission. No patient in the cohort underwent surgery in case of positive PCR test.

In this cohort, 9 patients had PCR-confirmed COVID-19+ (1.2%). Among them, 4 (0.5%) needed hospitalization for oxygen requirements. Two patients (0.3%) needed ICU and mechanical ventilatory support, and one died after 8 days in the ICU.

This patient was 67 years old, obese (BMI 31. 8) , and underwent open right lower lobectomy for adenocarcinoma (stage IA3). He became symptomatic 5 days after his discharge (influenza-like illness) and was tested for COVID-19 by PCR. After 48 hours of evolution at home, he required hospitalization and transfer to ICU for ARDS related to COVID-19. He finally died at post-operative day 23.

The total number of deaths was 22 (3%). Every death was tested for COVID-19. Only one death was COVID-19 related (0.14%).

The overall complication rate was 29.4% (216 cases). The most frequent complications were pneumonia (42/530 before lockdown and 10/204 after lockdown, p=0.49), followed by prolonged air leakage (39/530 before lockdown and 9/204 after lockdown, p=0.42) and postoperative atrial fibrillation (PAF, 26/530 versus 10/204, respectively, p=0.67). Other complications are detailed in Table 1 .

There was no difference in the complication rate before and after lockdown in our cohort (165/530 versus 51/204, p=0.12). Specific rate mortality are summarized in Table 4 (Supplementary data).

There were a total of 306 open surgeries and 428 minimally invasive surgeries. There were statistically fewer VATS surgeries after lockdown (p=0.02).

The median length of stay before confinement was 6 days (IQR=4) versus 5 days (IQR=3) after lockdown (p=0.24).

We compared the different precautions taken in the involved hospitals. The most important precaution concerns Milano since it was quickly decided that the European Institute of Oncology would not treat patients with severe forms of COVID-19 (Table 5 , supplementary data).

There is no difference in terms of COVID-19 results. There is also no difference in mortality between the two groups.

Additional subgroup analyses are available in the supplementary data.

Our results highlight safety and feasibility of thoracic malignancies surgery during COVID-19 pandemic. Indeed, mortality (3%) and morbidity (29.4%) were low, comparable to published data.

More, COVID-19 infection was only responsible of 1 out of the 22 deaths in the cohort (4.5%), and only 2 (0.3%) among the 731 patients needed ICU hospitalization due to COVID-19 infection.

The preliminary data on Asian cohorts 3,4 have led to a dramatic decrease in scheduled surgeries in Europe and North America. Among them, nearly 40% of surgeries cancelled or postponed were cancer surgeries 8 . In the field of thoracic oncology, many recommendations have suggested delaying surgery for peripheral localized non-small cell lung cancer (NSCLC) smaller than 2 cm (in patients with low risk of COVID-19 contamination) or 3-5 cm (in patients with high risk of COVID-19 contamination) 5, 7, 8 . In the meantime, the risk of cancer growth and/or metastasis, even in "small tumors", is expected, leading to lower chances of survival for these potentially curable patients. This delay in the management of localized NSCLC, even 3-4 months, can transform a localized tumor of less than 1 cm (T1a) into a tumor of 3-4 cm (T2a), decreasing the probability of 5-year survival from 92% to 68%, worsening to 53% in the mere case of hilar lymph node involvement (TNM 8 th edition 9 ).

This idea is reinforced by Nepogodiev et al.'s publication 10 . Indeed, in their estimation, the authors concluded that it would take approximately 45 weeks to clear the backlog of operations resulting from COVID-19 disruption, despite a 20% increase in surgical activity 10 . Under these conditions, it can be estimated that the delay in the treatment of these pathologies will lead to more advanced disease at the time of surgery, including metastatic patients who are no longer suitable for curative treatment. In support of this, a meta-analysis focusing on delayed treatment in oncology was published in November 2020 11 . After inclusion of more than 1.2 million patients for different indications, a 6 to 8% increase in mortality depending on histological type was found for a 4-week delay in surgical treatment 11 . Moreover, the switch from surgical treatment to systemic therapies (such as targeted therapies or immunotherapies) due to postponed surgery undoubtedly has a significant medicoeconomic impact.

Our results do not support thoracic malignancies and thoracic surgery as risk factors for poor outcomes in the current COVID-19 era. Indeed, the expected mortality rate related to COVID-19 in the general population, as reported by the WHO, is 0.28% 12 . In our cohort, the rate of severe events was 0.3%, with a very low rate of death (0.14%). Moreover, the median age of the studied population was 67 years, and according to the WHO, the overall mortality rate in this population is estimated to be 3.6% in the latest estimates. Markedly, two of the patients who underwent pneumonectomy (68 and 83 years old) and who were found to be COVID-19+ had surprisingly positive courses.

Other historical pandemics have already threatened the healthcare system, with the most recent example being SARS-CoV between 2002 and 2004 in Hong Kong and China. It does not seem unrealistic to hypothesize that the COVID-19 pandemic will not be the last one. The medical system has consequently to learn from these pandemics and adapt its practices to offer care to all patients. We have highlighted here that the pursuit of treatment for thoracic malignancies in highly infected regions during a pandemic period is feasible and does not lead to substantial excess mortality, since 1 death out of 22 was COVID-19 related. Indeed, even though the very large majority of ICU beds were converted into COVID-19+ beds, we did not observe higher postoperative mortality than that observed during a nonpandemic period. On the other hand, we did not observe an increased risk of in-hospital contamination, since only 5 (0.7%) patients tested positive after their hospitalization. These findings J o u r n a l P r e -p r o o f can be partially explained by the reinforcement of our Enhanced Recovery After Surgery (ERAS) 13 program in the majority of the hospitals in our study, which limited the hospital length of stay.

Furthermore, since ICU beds were transformed into COVID-19+ beds, recovery rooms were transformed into a non-COVID-19 ICU zone, allowing the maintenance or transfer of sick patients in the postoperative period and limiting the risk of contamination by a COVID-19+ patient. However, we emphasize that maintaining a surgical activity during COVID-19 pandemic depends on several factors related to hospitals, including material (respiratory machine), health-care providers, bed availability, as well as the intensity of the pandemic itself. Equally, the maintenance of "non-COVID-19" care channels such as EBUS or Pulmonary Function Test (PFT) is a necessity to perform thoracic surgery for malignancy.

To improve management, we compared the precautionary measures taken during the study. The most important measure was the preservation of the European Institute of Oncology in Milano. However, subgroup analysis of only one center compared to the others does not allow us to conclude on the benefit of this precaution. Further studies will be necessary to determine the best preventive measure against COVID-19.

Our study has some limitations that must be taken in account when analyzing the results. Although the data were prospectively collected this is a retrospective cohort study. Moreover, the heterogeneity of prevention measures taken, depending on each country, does not allow to identify the best way to proceed. Nevertheless, it shows that different measures can be applied to provide safety to patients and healthcare providers as well.

On the other hand, our study is strengthened by its multi-institutional design, providing clinical data on the largest published cohort of patients who underwent thoracic malignancy surgery during COVID-19 pandemic. Finally, the proportion of COVID-19 PCR test was relatively low, forbidding to draw any conclusion on the consequences of COVID-19 infection on thoracic cancer surgery outcomes. Indeed, our cohort included 66 patients who did not benefit from systematic PCR prior to surgery during the lockdown period (only in France), so we may have underestimated the rate of COVID-19 patients, especially asymptomatic cases. We can also point out that due to the variable incubation period of COVID-19 infection (between 2 and 12 days 14 ), it does not seem reasonable to J o u r n a l P r e -p r o o f 9 conclude on the time of infection (before, during or after hospitalization). However, the aim of this study was to evaluate the safety of maintaining a surgical activity during COVID-19 pandemic.

The maintenance of surgical activity, particularly in oncology, appears necessary in light of the excess mortality from all causes observed during the first months of 2020. Indeed, part of the excess mortality observed is linked to the absence of or delay in the management of non-COVID pathologies 15 . The absence of the diagnosis of myocardial infarction has been well documented 16 , as well as the delay in cancer diagnosis 17 .

In conclusion, in this large international multi-institutional study, we have shown that maintaining surgical thoracic oncology activity in the era of COVID-19 is feasible and safe. Since surgery is associated with the best outcomes in thoracic malignancies, thoracic cancer patients should still be operated on. We emphasize that every measure should be taken to protect healthcare providers and limit the risk of operating on COVID-19+ patients. More data on other malignancies are necessary.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics)

Covid-19 Outbreak Progression in Italian Regions: Approaching the Peak by the End of March in Northern Italy and First Week of April in Southern Italy

Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

LUNG CANCER SURGICAL MANAGEMENT DURING THE OUTBREAK OF COVID-19

Challenges in lung cancer therapy during the COVID-19 pandemic

Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic

Treatment guidance for lung cancer patients during the COVID-19 pandemic

The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM J o u r n a l P r e -p r o o f Classification of Lung Cancer

Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans: Elective surgery during the SARS-CoV-2 pandemic

Mortality due to cancer treatment delay: systematic review and meta-analysis

Situation Report-41

Feasibility analysis for the development of a video-assisted thoracoscopic (VATS) lobectomy 23-hour recovery pathway

Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research

DOHMH) COVID-19 Response Team, New York City Department of Health and Mental Hygiene (DOHMH) COVID-19 Response Team

The Obstacle Course of Reperfusion for STEMI in the COVID

Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands